A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three ...

With investors and drugmakers increasingly eyeing the kidney disease space, a new company hopes to shed its underdog status ...

Next month will be the first opportunity to gauge the commercial launch of a new treatment for Prader-Willi syndrome, a rare ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

The idea of making the U.S. more like Europe is anathema to many in the Trump administration. But that’s what the Make ...

The U.S. has now recorded more confirmed measles cases this year than in any year in well over a quarter-century.

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Nearly 1 in 3 American adolescents have prediabetes, a CDC report finds. An official notes "it’s not too late to change ...

Summa Health's experience with Sepsis Watch shows the difficulties in implementing AI in a community hospital.

The lack of information on new ACIP appointees stands in stark contrast to the detailed conflict-of-interest database for ...

The Medicare Advantage industry has aggressively sued the federal government to overturn reduced quality ratings and keep ...